Lamassu
ACCELERATING HOPE AND HEALING

10000 Cedar Avenue
Cleveland, OH 44106
(919) 667-8571
www.LamassuBiotech.com

THE UNMET NEEDS

Chemotherapy is not selective and comes with significant side effects, with less desirable effectiveness. Some types of cancer such as de-differentiated liposarcoma have very poor outcomes.

SCIENCE

- Potential best in class MDM2 inhibitor.
- Small molecule, successful scale up and transfer to commercial manufacturing partner. 1.25 KG GMP grade achieved 99.7% purity.
- Big market, potentially 50% of all cancer patients can be qualified for SA53.
- Known predictive biomarker to improve the chance of success.
- Proven mechanical of action. No drug approved on market yet targeting MDM2. Superior to potential competitors in head-to-head in animal studies (potential competitors are in clinical trial).
- Monotherapy or combination therapy, we have high synergy with many major cancer drugs.
- Oral administration, only 1-4 pills/ month.

SA53: Novel therapeutic now entering first human trials

- New oncology class, precision oncology: Genetically targeted therapy MDM2 inhibitor / p53 activating therapy
- p53, "guardian of the genome", is the body's natural defense against cancer. It can be reactivated by SA53 to halt and kill the tumor cells.

P53 Pathway Protects Cells From Malignant Transformation



POTENTIAL BEST IN CLASS BASED ON PRECLINICAL COMPARISON TESTING



EXPERIENCED TEAM

Seasoned entrepreneurs and oncology experts.

Gabi Hanna, MD
Chief Executive Officer

- *Research focus on oncology, translational medicine*
- *Duke oncology IRB member for over 10 years*
- *Executive Director of Duke Preclinical Translational Research Unit*

Greg Palmer, PhD
Chief Science Officer

- *Director of Duke University Cancer Institute, Imaging Facility*
- *Expertise in imaging, medical devices, and translational science*

Rabi Hanna, MD
Co-Founder

- *Chair of Pediatric Oncology at Cleveland Clinic Foundation*
- *Lead investigator for multiple oncology clinical trials for novel therapies*
- *Translational and clinical expertise*
- *Serves as an advisory board member to several biotech companies and as a board member of the Federation for the Accreditation of Cellular Therapies (FACT)*

PUMA



P21



Over 10 years of R&D. Extensive discovery process selected from 2000 tested compounds, and over 100 animal studies in five species.

DEVELOPMENT STATUS

- FDA approved IND to start phase I/II.
- Starting first in human trial at Cleveland Clinic as leading site.
- Supported by a grant from NIH/NCI for novel oncology therapy.
- Supported by another partnering peer review grant from Quebec Canada (CQDM).
- Early development supported by a European grant.
- Strong science and development plan, led to receipt of significant non-dilutive peer-reviewed funding.
- Partnering with key oncology experts in academia and industry to persue multiple indications and combination therapies (science and patient centered partnership rather than financial).



STRATEGIC PARTNERS

NIH National Cancer Institute
NIH National Institutes of Health
Université de Montréal
cqdm
Mayo Clinic
Cleveland Clinic
SAYDI BIOTECH
McGill University
ADAMED
ARRIVO BIOVENTURES

Most promising combinations

+ BTK
+ BRAF/MEK
+ CDK4/6
+ Topoisomerase (doxorubicon)

Main criteria

✓ Synergy score δ >5
✓ Route of administration *per os*
✓ Compatible side effects
✓ Different MoA
✓ Different MoA resistance

Inhibitor Class	Mean δ score value*	% of synergistic combination	N of Models	Rout of Administration
BTK Inhibitor	19	50	2	PO
BRAF Inhibitor	12	67	3	PO
MEK Inhibitor	9	82	11	PO
CDK4/6 Inhibitor	8	29	7	PO
Topoisomerase Inhibitor	11	55	11	IV
Tubulin Inhibitor	11	13	16	IV
Antimetabolite	7	75	4	PO
P13K Inhibitor	6	25	4	PO
Bcr-Abl Inhibitor	-	0	2	PO
Proteasome Inhibitor	-	0	2	IV
AR Inhibitor	-	0	1	PO

● 5-10 Synergy ● >10 Strong Synergy

CONTACT

Dr. Gabi Hanna, Chief Executive Officer
gabi.hanna@lamassupharma.com
+1.919.667.8571
www.LamassuBiotech.com

IP AND REGULATORY

- Exclusive global license for 69 countries, granted patent in most.
- Regulatory advantage: IND approved for rapid clinical advancement with combined Phase I/II, potential FDA fast track, and breakthrough.
- Potential priority voucher targeting rare oncology.